RTI Surgical® & Aziyo® Biologics Announce Exclusive Agreement to Distribute ViBone® for Spine & Other Orthopedic Procedures
August 01 2018 - 8:05PM
Business Wire
Agreement will expand availability of ViBone, a
next generation cellular bone matrix product
RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant
company, and Aziyo Biologics, Inc., a fully integrated regenerative
medicine company, today announced the signing of an agreement under
which Aziyo will provide ViBone to RTI Surgical for exclusive
distribution in the U.S.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180801006112/en/
ViBone is a bone repair product designed to perform and handle
more closely to autograft in a variety of orthopedic procedures.
ViBone is processed using a proprietary method optimized to protect
and preserve the health of native bone cells to potentially enhance
new bone formation.
“ViBone is a next generation bone graft product that meets the
diverse needs of surgeons with high potential for improved outcomes
for patients,” said Camille Farhat, President and CEO, RTI
Surgical. “ViBone will join RTI’s existing biologic portfolio as
another important option for surgeons.”
RTI’s company strategy centers on organic and acquisitive growth
focused on differentiated products supported by clinical data.
RTI’s commercial team will integrate ViBone into its sales and
growth strategy in the U.S., effective immediately. Together, RTI
and Aziyo will initiate new research on ViBone in the coming months
to build on the characterization and other data currently
available.
“We are excited to partner with RTI Surgical, a recognized
leader in spine and tissue-based implants, to bring this innovative
option to more surgeons, and to further investigate the value it
provides to patients,” said Ron Lloyd, President and CEO, Aziyo
Biologics. “This agreement provides a platform for RTI and Aziyo to
mutually grow and expand in the spinal fusion and orthopedic
markets in service to more patients.”
About ViBone
ViBone is a next generation viable bone matrix that was designed
to perform and handle more like high quality autograft. Aziyo’s
proprietary manufacturing process was designed to optimally protect
the tissue environment with less disruption. ViBone is based on
science that brings bone grafting closer to meeting the surgeon and
patient’s needs and provides a better option for bone repair. To
learn more about ViBone, visit www.Aziyo.com/ViBone/.
About RTI Surgical, Inc.
RTI Surgical is a leading global surgical implant company
providing surgeons with safe biologic, metal and synthetic
implants. Committed to delivering a higher standard, RTI’s implants
are used in sports medicine, general surgery, spine, orthopedic and
trauma procedures and are distributed in nearly 50 countries. RTI
has four manufacturing facilities throughout the U.S. and Europe.
RTI is accredited in the U.S. by the American Association of Tissue
Banks and is a member of AdvaMed. For more information, please
visit www.rtix.com.
About Aziyo Biologics, Inc.
Aziyo Biologics is a fully integrated, commercially oriented
regenerative medicine company. Since its founding in 2015 the
Company has expanded through acquisitions and strategic
partnerships, creating a high growth commercial entity. Its
proprietary products are used in orthopedic, cardiovascular and
other medical specialties. For more information, visit
www.Aziyo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180801006112/en/
RTI Media ContactMolly Poarch,
+1-224-287-2661mpoarch@rtix.comorRTI Investor ContactNathan
Elwell,
+1-847-530-0249nelwell@lincolnchurchilladvisors.comorAziyo Media
ContactCourtney Guyer, +1-510-730-7896PR@aziyo.com
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Sep 2023 to Sep 2024